LGR5 and colorectal carcinoma: LGR5 is involved in promoting tumor progression via EMT and WNT/β-catenin pathways and increased LGR5 expression is associated with chemotherapy resistance and recurrence in different cancers including breast, cervical, CRC, gastric, HCC and ovarian carcinoma.